全文获取类型
收费全文 | 9999篇 |
免费 | 456篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 167篇 |
妇产科学 | 80篇 |
基础医学 | 1264篇 |
口腔科学 | 273篇 |
临床医学 | 682篇 |
内科学 | 3099篇 |
皮肤病学 | 207篇 |
神经病学 | 560篇 |
特种医学 | 343篇 |
外科学 | 1502篇 |
综合类 | 37篇 |
预防医学 | 393篇 |
眼科学 | 190篇 |
药学 | 682篇 |
中国医学 | 16篇 |
肿瘤学 | 926篇 |
出版年
2023年 | 60篇 |
2022年 | 123篇 |
2021年 | 194篇 |
2020年 | 110篇 |
2019年 | 121篇 |
2018年 | 174篇 |
2017年 | 140篇 |
2016年 | 169篇 |
2015年 | 176篇 |
2014年 | 221篇 |
2013年 | 271篇 |
2012年 | 415篇 |
2011年 | 476篇 |
2010年 | 237篇 |
2009年 | 224篇 |
2008年 | 450篇 |
2007年 | 471篇 |
2006年 | 438篇 |
2005年 | 466篇 |
2004年 | 471篇 |
2003年 | 424篇 |
2002年 | 448篇 |
2001年 | 299篇 |
2000年 | 300篇 |
1999年 | 259篇 |
1998年 | 113篇 |
1997年 | 85篇 |
1996年 | 89篇 |
1995年 | 78篇 |
1994年 | 94篇 |
1993年 | 80篇 |
1992年 | 271篇 |
1991年 | 234篇 |
1990年 | 191篇 |
1989年 | 245篇 |
1988年 | 211篇 |
1987年 | 223篇 |
1986年 | 220篇 |
1985年 | 195篇 |
1984年 | 125篇 |
1983年 | 97篇 |
1982年 | 49篇 |
1981年 | 45篇 |
1979年 | 82篇 |
1978年 | 55篇 |
1977年 | 49篇 |
1972年 | 45篇 |
1971年 | 45篇 |
1969年 | 48篇 |
1968年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Long-term effect of urokinase therapy in IgA nephropathy 总被引:4,自引:0,他引:4
Effects of urokinase (UK) therapy in patients with moderate to advanced degrees of IgA nephropathy (IgAN) were examined. Twenty-seven patients were treated by "two weeks" UK administration, 14 patients were treated by "consecutive" UK administration and 16 patients were treated by antiplatelet drugs. There were marked improvements in urinary protein concentration, serum creatinine and blood urea nitrogen after UK therapy, especially in patients treated by "consecutive" UK administration which was performed by "single shot" UK injection. Clinical prognosis was favorable in patients treated by UK administration compared with those given antiplatelet treatment. It was concluded that "consecutive" UK administration might be useful for treatment of IgAN with moderate to advanced renal injuries. 相似文献
52.
Health risk appraisal (HRA) is a new health educational tool widely-used in the United States, which informs clients about how their health habits and lifestyles affect their probability of dying from potentially preventable causes and helps to motivate them to reduce their personal health risks. It personalizes mortality statistics and epidemiologic data by combining these data with a person's risk factors. We have got started the development of HRA for Japanese with reference to a new version of HRA named "Healthier People" revised by the Carter Center of Emory University and the Centers for Disease Control in the United States. 相似文献
53.
Tomoko Yoshinari Yoshikazu Iwasawa Keiko Miura Ikuko S. Takahashi Takahiro Fukuroda Kunio Suzuki Akira Okura 《Cancer chemotherapy and pharmacology》1989,24(6):367-370
Summary BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1–2 M, whereas they showed hardly any synergistic effect in the parental cell line (P388/S) at the same concentration. They inhibited the active drug efflux in P388/ADR cells as well as the binding of [G-3H]-vinblastine to membrane vesicles from P388/ADR, which was increased in resistant P388 cells as compared with parental cells. Besides, unlike the activity of clinically used calcium antagonists, the calcium antagonistic activity associated with BS compounds was very weak: their arterial relaxation activity was <21% of that of verapamil. These data suggest that BS compounds specifically overcome multidrug resistance without the serious hypotensive side effects that accompany the use of verapamil orother calcium antagonists. 相似文献
54.
Jun Ishigooka Mitsukuni Murasaki Hirobumi Wakatabe Sadanori Miura Kozo Hikida Masahiro Shibata 《Psychopharmacology》1989,97(3):303-308
The pharmacokinetic properties of the iminodibenzyl antipsychotic drugs clocapramine (CCP, 3-chloro-5-[3-(4-carbamoyl-4-piperidino piperidino) propyl]-10, 11-dihydro-5H-dibenzo[b, f]azepine) and Y-516 (3-chloro-5-[3-(2-oxo-1, 2, 3, 5, 6, 7, 8, 8a-octahydroimidazo [1,2-a] pyridine-3-spiro-4-piperidino) propyl]-10, 11-dihydro-5H-dibenzo[b, f]azepine) were investigated in dog and man. Dogs were administered CCP and Y-516 intravenously, intraperitoneally, and orally, and the concentrations of the parent drugs and their metabolites in the plasma and urine were determined. Half-life (t1/2) was approximately the same by all three administration routes, being approximately 5 h for CCP and 3 h for Y-516. Bioavailability following oral administration was 0.16±0.01 (mean ± SD, n=3) for CCP and 0.29±0.07 for Y-516. The fractions of dose absorbed following oral administration were 0.43±0.07 and 0.79±0.24, and the fractions of dose metabolized in the liver due to the first-pass effect were 0.63±0.05 and 0.63±0.04 for CCP and Y-516, respectively. Y-516 was detected in the plasma after intraperitoneal and oral administration of CCP. The ratio of the AUC of Y-516 to that of CCP was 0.06 following intraperitoneal administration and 0.40 following oral administration. This indicated that while the metabolism of CCP into Y-516 may occur partly in the liver due to the first-pass effect, it occurs mostly within the gastrointestinal tract itself or its mucosa. When CCP and Y-516 were given orally to man, the plasma concentrations of both parent drugs increased in a dose-dependent manner. The t1/2 of CCP at a dose of 50 mg was 46±6 h (n=3) while that of Y-516 at a dose of 25 mg was 15±2 h (n=5), so that elimination from the circulation was slower than in the dog in both cases. As in the dog, Y-516 was detected in the plasma following administration of CCP, but its concentration was approximately one fifth that of CCP and lower than that found in the dog. From the ratios of Y-516 produced upon oral administration of CCP in dog and man, we concluded that Y-516 is involved to a considerable degree in the pharmacological action of CCP in the dog and, though to a lesser degree, in man as well. 相似文献
55.
Suzuki Hisamitsu; Ota Kazuo; Ohno Ryuzo; Masaoka Toru; Shibata Hirotoshi; Kimura Ikuro; Amaki Ichita; Miura Yasusada; Uzuka Yoshiro; Kawato Masafumi; Shirakawa Shigeru; Hirota Yutaka; Maekawa Tadashi; lmai Kuniyuki; Takaku Fumimaro; Shimoyama Masanori; Kitahara Takeshi; Oguro Masao; Kozuru Mitsuo; Kawagoe Hiroya; Nakamura Toru; Yamada Kazumasa 《Japanese journal of clinical oncology》1989,19(4):338-347
Patients with acute (2,569) and chronic (957) leukemia diagnosedat 19 institutes took part in the study on the "MultidisciplinaryTreatment of Leukemia" between 1971 and 1985 and were investigatedretrospectively. By dividing the 15 years into three five-yearperiods, we were able to compare patient ratios in the differentperiods. The proportions of acute to chronic leukemia casesshowed no obvious change; however, the proportions of casesdiagnosed as acute lymphocytic leukemia in acute leukemia showeda significant increase. The main chemotherapeutic drugs usedduring the three time periods were cytarabine or its analogues,the anthracyclines, 6-mercaputopurine and prednisolone, againstacute myelogenous leukemia, and the vinca alkaloids, prednisoloneand the anthracyclines against acute lymphocytic leukemia. Therate of complete remission from acute myelogenous leukemia mademarked progress, from 45.1% during 19711975 to 62.3%during 19811985, but that of acute lymphocytic leukemiashowed no significant progress, being 65% during 19711975and 69.7% during 19811985. The durations of remission,however, and the survival times for patients with acute lymphocyticleukemia, as well as for those with acute myelogenous leukemia,became significantly longer over the three periods. Median survivaltimes from chronic myelocytic leukemia were 3740 mo inall three periods, showing no progress. There was a better prognosisin cases of chronic myelocytic leukemia with, than without,Philadelphia chromosome. Except for a low incidence of chroniclymphocytic leukemia in Japan, adult leukemia patients' characteristicsand prognoses seem to be almost the same in Japan as in theU.S.A. and Europe. 相似文献
56.
Detection of polymeric IgA in glomeruli from patients with IgA nephropathy. 总被引:4,自引:8,他引:4 下载免费PDF全文
A study on the detection of polymeric IgA in glomeruli from renal biopsy specimens in patients with IgA nephropathy is described. Renal biopsy specimens were obtained from patients with IgA nephropathy. These specimens were stained with FITC-labelled anti-human J chain antisera and then examined with a fluorescent microscope. The J chain was observed in the glomerular mesangium by immunofluorescent staining. In parallel studies, renal biopsy specimens were treated with citrate buffer (pH 3.2) and the 'eluate' was neutralized by sodium hydroxide. The eluate was labelled with iodine-125, and the radiolabelled 'eluate' was fractionated by sucrose density-gradient ultracentrifugation. Polymerized IgA in the 'eluate' obtained from patients with IgA nephropathy was found to sediment predominantly as 9S to 11S using a sucrose density gradient analysis. Polymeric IgA in the fractions of the density gradient analysis was determined by anti-human IgA and anti-human J chain antisera. It was demonstrated that IgA and J chain were eluted from the glomeruli in some patients with IgA nephropathy. It is concluded that IgA deposited in the glomeruli is composed of dimers and/or larger polymers of circulating IgA in some patients with IgA nephropathy. 相似文献
57.
Yozo Miura Yuzo Morimoto Masayoshi Kinoshita 《Macromolecular chemistry and physics.》1974,175(12):3487-3493
2,4,6-Triphenyl-3,4-dihydro-s-tetrazin-1(2H)-yl ( 1 ) (1,3,5-triphenylverdazyl) was allowed to react with ethyl- and butyllithium, ethyl-, isopropyl-, and butylmagnesium bromide, as well as benzylmagnesium chloride to give the coupling products 2a–d . These results indicate that structures corresponding to 2 are present in the polymers resulting from vinyl monomers containing the verdazyl structure, if they are initiated with alkyllithium or a Grignard reagent. A reaction mechanism is discussed. 相似文献
58.
Shibata M Kanamori S Ohsawa Y Watanabe T Yayoi Y Miura M Kominami E Uchiyama Y 《Archives of histology and cytology》2001,64(1):17-28
CED-9 prevents apoptosis in embryonic cells of Caenorhabditis elegans but not in mammalian cells. We show here that the prevention of apoptosis in mammalian cells requires a CED-3-cleaved form (68-280) of CED-9 which is localized in the inner mitochondrial membrane. The viability of PC12 and HeLa cells was significantly increased after death stimuli when truncated CED-9 was expressed in these cells but full-length CED-9 did not. The truncated CED-9 expressed in these cells was largely localized to the inner mitochondrial and the endoplasmic reticulum membranes, while full-length CED-9 was detected mainly in endoplasmic reticulum fractions. Moreover, truncated CED-9 in purified mitochondria was resistant to trypsin digestion, but full-length CED-9 was not. These results suggest that the CED-3-cleaved form of CED-9 prevents apoptosis in mammalian cells by localizing to the inner mitochondrial membrane. 相似文献
59.
Koichiro Yuji Shigesaburo Miyakoshi Daisuke Kato Yuji Miura Tomohiro Myojo Naoko Murashige Yukiko Kishi Kazuhiro Kobayashi Eiji Kusumi Hiroto Narimatsu Tamae Hamaki Tomoko Matsumura Masahiro Kami Takahiro Fukuda Shigeru Masuo Kazuhiro Masuoka Atsushi Wake Junichi Ueyama Akiko Yoneyama Ko Miyamoto Haruhisa Nagoshi Michio Matsuzaki Shinichi Morinaga Yoshitomo Muto Yoichi Takeue Shuichi Taniguchi 《Biology of blood and marrow transplantation》2005,11(4):314-318
We report the results of reduced-intensity unrelated cord blood transplantation (RI-UCBT) in patients with advanced malignant lymphoma. Twenty patients (median age, 46.5 years; range, 27-66 years) underwent RI-UCBT with a preparative regimen consisting of fludarabine 125 mg/m2 , melphalan 80 mg/m 2 , and 4 Gy of total body irradiation. The median infused total cell dose was 2.75 x 10(7)/kg (range, 2.3-3.4 x 10(7)/kg). Graft-versus-host disease (GVHD) prophylaxis was composed of cyclosporine or tacrolimus alone. Fifteen patients achieved primary neutrophil engraftment after a median of 20 days. Eight patients developed grade II to IV acute GVHD, and 2 developed chronic GVHD. Of the 16 patients with evaluable disease, 10 achieved a complete response. Primary disease recurred in 1 patient, and transplant-related mortality within 100 days occurred in 8 of 20 patients. The estimated 1-year probability of progression-free survival was 50%. These data suggest that RI-UCBT is a feasible option for patients with refractory lymphoma who lack an HLA-matched donor. 相似文献
60.
Our previous study showed that the saliency of a target increases the gain of smooth pursuit initiation. In this study, we examined the interocular transfer of this effect in five humans. A square red frame surrounding the target was used as a cue to indicate the initial target position. In the cue condition, the responses were similar, irrespective of the eye to which the cue was presented, and were significantly larger than in the no-cue condition. The result suggests that central pathways that receive input from both eyes mediate the effect of saliency on smooth pursuit initiation. 相似文献